Company description

Biogen Inc. (BIIB) is a leading biotechnology company that specializes in the development and manufacturing of innovative therapies for neurological, autoimmune, and rare diseases. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Through its extensive research and development efforts, Biogen has developed a diverse portfolio of products with a strong focus on neurodegenerative diseases such as Alzheimer's, Parkinson's, and Multiple Sclerosis. Its flagship drug, Tysabri, has been a major success for the company, generating over 1 billion dollars in annual revenue. In addition to its focus on neurology, Biogen also has a strong presence in immunology, hematology, and ophthalmology. The company's mission is to transform patient lives through cutting-edge science, innovation, and compassionate care. Biogen has a global reach with operations in more than 50 countries and is committed to making a positive impact in the healthcare industry. With a dedicated team of over 7,000 employees worldwide, Biogen continues to push the boundaries and advance treatments for some of the world's most challenging diseases.